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Heat-stable enterotoxin peptides (ST’s) are expressed by enterotoxigenic strains of 
bacteria in order to co-opt an endogenous ligand-receptor system that regulates fluid 
homeostasis within the gut. Bacteria such as E. coli, V. Cholerae, and Y. 
enterocolitica have evolved ST’s which mimic native guanylin/uroguanylin peptides 
by activating guanylate cyclase C (GC-C), yet possess increased resistance to 
heat/enzymatic degradation as well as superagonist activity by virtue of a third 
disulfide bond. We have previously utilized ST peptides derived from an E. coli 
isolate, as well as analogs of the endogenous peptide hormone uroguanylin, as 
imaging and therapeutic agents for GC-C-expressing colorectal cancers. In this work, 
we have compared the ability of these peptides to target GC-C and engender 
production of cGMP with that of an ST analog derived from Yersinia enterocolitica. 
Previous results had suggested that the Y. enterocolitica sequence may elicit higher 
cyclase activity than other peptides in this class. We have generated the peptide 
GENDWDWCCELCCNPACFGC both with and without an N-terminal DOTA 
chelating moiety and characterized its receptor binding affinity and ability to 
stimulate cGMP production in comparison to other peptides in this class. Our findings 
indicate that the Yersinia peptide possesses receptor binding affinity and cyclase 
stimulating activity intermediate between known E. coli ST analogs and human 
uroguanylin. However, in vivo biodistribution results obtained using the 64Cu-labeled 
DOTA-peptide demonstrated normal tissue distributions substantially different from 
E. coli-derived peptides, and more akin to those obtained with radiolabeled 
uroguanylin peptides.   
 
